Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 10/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 10/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 10/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30451773 | 0.81 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL28484184 | 0.74 | PI4KA (0.42) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL21518150 | 0.70 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL21518153 | 0.70 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL29641197 | 0.70 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL21590119 | 0.69 | PI4KA (0.48) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL2449991 | 0.69 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL28484182 | 0.69 | PI4KA (0.44) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL28921930 | 0.68 | CYP3A4 (0.57) | LMNAHPGDSMN1; SMN2ADORA2AADORA1 | |
| SCHEMBL30451824 | 0.67 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210179647-A1 | PHOSPHONAMIDE ESTER COMPOUND, SALT THEREOF, RELATED CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-06-17 | — | — | US | claimed |
| EP-3808752-A1 | PHOSPHONAMIDE ESTER COMPOUND, SALT THEREOF, RELATED CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2021-04-21 | — | — | EP | claimed |
| US-11186599-B2 | Phosphonamide ester compound, salt thereof, related crystal form thereof, preparation method therefor and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-11-30 | — | — | US | disclosed |
| US-20210179647-A1 | PHOSPHONAMIDE ESTER COMPOUND, SALT THEREOF, RELATED CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-06-17 | — | — | US | disclosed |
| EP-3808752-A1 | PHOSPHONAMIDE ESTER COMPOUND, SALT THEREOF, RELATED CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2021-04-21 | — | — | EP | disclosed |
| US-10899786-B2 | Nucleoside phosphate compound and preparation method and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-01-26 | — | — | US | disclosed |
| US-20200308214-A1 | NUCLEOSIDE PHOSPHATE COMPOUND AND PREPARATION METHOD AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| EP-3560943-A1 | NUCLEOSIDE PHOSPHATE COMPOUND AND PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2019-10-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308214-A1 | NUCLEOSIDE PHOSPHATE COMPOUND AND PREPARATION METHOD AND USE THEREOF | PNP, NTPCR, TYMP | PI4KA 742/4885PI4K2B 776/4885PI4K2A 1030/4885 |
| US-10899786-B2 | Nucleoside phosphate compound and preparation method and use thereof | PNP, NTPCR, TYMP | PI4KA 742/4885PI4K2B 776/4885PI4K2A 1030/4885 |
| US-20210179647-A1 | PHOSPHONAMIDE ESTER COMPOUND, SALT THEREOF, RELATED CRYSTAL FORM THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | SLC10A1, PYGL, HASPIN | PI4KA 459/4885PI4K2B 647/4885PI4K2A 945/4885 |
| US-11186599-B2 | Phosphonamide ester compound, salt thereof, related crystal form thereof, preparation method therefor and use thereof | SLC10A1, PYGL, HASPIN | PI4KA 459/4885PI4K2B 647/4885PI4K2A 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.